Ruboxistaurin
 | |
 | |
| Systematic (IUPAC) name | |
|---|---|
| (9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20-dione | |
| Clinical data | |
| Identifiers | |
169939-94-0  | |
| None | |
| PubChem | CID 153999 |
| ChemSpider |
135727  |
| UNII |
721809WQCP |
| ChEMBL |
CHEMBL91829 |
| Chemical data | |
| Formula | C28H28N4O3 |
| 468.546 g/mol | |
| |
| (what is this?) (verify) | |
Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic peripheral retinopathy being investigated by Eli Lilly and Company. It is a member of the bisindolylmaleimide family.
On February 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an "approvable" letter from the United States Food and Drug Administration for ruboxistaurin,[1] with a request for an additional clinical trial, which would take 5 years to complete.[2]
Mechanism of action
Ruboxistaurin is an inhibitor of protein kinase C-beta.[3]
References
- ↑ "Drugs.com, Eli Lilly and Company Announces Approvable Letter Issued by FDA for Arxxant". Retrieved 2008-02-15.
- ↑ "Drugs.com, Lilly Announces FDA Requirement of Additional Clinical Trial Before Ruboxistaurin Could Be Approved for Treatment of Diabetic Retinopathy". Retrieved 2008-02-15.
- ↑ Clarke M, Dodson PM (December 2007). "PKC inhibition and diabetic microvascular complications". Best Pract Res Clin Endocrinol Metab 21 (4): 573–86. doi:10.1016/j.beem.2007.09.007. PMID 18054736.